findmyKOL
Clinical trialNCT05861895RecruitingPhase 1Interventional

HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors

SponsorHighField Biopharmaceuticals CorporationEnrollment84Solid Tumors, Adult
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China

    Kai Yao
    Recruiting
United States
  • Mary Crowley Cancer Research

    Dallas, Texas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

HF158K1 / 1.4 g lipid doseHF158K1 / 2.2 g lipid doseHF158K1 / 2.9 g lipid dose
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
12 Dec 2023
Primary completion
23 Jun 2027
Completion
23 Dec 2027
Last update posted
26 Jun 2026
Registered enrollment
84
Registry id
NCT05861895
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.